By Michael Dabaie


Eli Lilly & Co. said Health Canada approved Taltz for the treatment of adult patients with active non-radiographic axial spondyloarthritis, or nr-axSpA.

Axial spondyloarthritis, which includes both ankylosing spondylitis and nr-axSpA, is a disease that predominantly affects the sacroiliac joints and the spine, which results in chronic inflammatory back pain and fatigue.

This is the fourth indication for Taltz, which was first approved by Health Canada for moderate-to-severe plaque psoriasis in 2016, psoriatic arthritis in 2018, and ankylosing spondylitis in 2020.

"People living with non-radiographic axial spondyloarthritis suffer through considerable pain and other symptoms of inflammation for as long as ten years before being accurately diagnosed. Limited treatment options exacerbate this challenge," said Doron Sagman, vice president of R&D and medical affairs for Eli Lilly Canada.


Write to Michael Dabaie at


(END) Dow Jones Newswires

October 19, 2020 09:01 ET (13:01 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Eli Lilly Charts.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Eli Lilly Charts.